Drozitumab

Drozitumab (PRO 95780) is a human agonistic monoclonal antibody which binds the death receptor DR5. Drozitumab has potent antitumor activity against rhabdomyosarcoma[1][2][3].

Product Specifications

CAS Number

[912628-39-8]

Product Name Alternative

PRO 95780; rhuMAb-DR 5; Anti-Human DR5 Recombinant Antibody

UNSPSC

12352203

Target

Apoptosis

Type

Inhibitory Antibodies

Related Pathways

Apoptosis

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/drozitumab.html

Purity

99.00

Solubility

H2O

Smiles

[Drozitumab]

Molecular Weight

(143.06 kDa)

References & Citations

[1]Dine JL, et al. The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl. Breast Cancer Res Treat. 2016 Jan;155 (2) :235-51. |[2]Kang Z, et al. Drozitumab, a human antibody to death receptor 5, has potent antitumor activity against rhabdomyosarcoma with the expression of caspase-8 predictive of response. Clin Cancer Res. 2011 May 15;17 (10) :3181-92.|[3]Eng JW, et al. Pancreatic cancer stem cells in patient pancreatic xenografts are sensitive to drozitumab, an agonistic antibody against DR5. J Immunother Cancer. 2016 Jun 21;4:33.